Quantcast

Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

By GlobeNewswire,  September 20, 2018, 04:05:00 PM EDT

Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology


CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, October 2, 2018, at 9:00 a.m. ET.

A live audio webcast will be available within the Investor and News section of the Rubius Therapeutics' website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on Twitter.



Media Contact:

Dan Budwick

1AB, Inc.

+1 (973) 271-6085

dan@1abmedia.com

Investor Contact:

Lori Melançon

Vice President, Corporate Communications and Investor Relations

+1 (617) 229-6122

lori.melancon@rubiustx.com

Source: Rubius Therapeutics

This article appears in: News Headlines

Referenced Stocks: RUBY








Today's Market Activity

NASDAQ 7247.87
-11.16  ▼  0.15%
DJIA 25413.22
123.95  ▲  0.49%
S&P 500 2736.27
6.07  ▲  0.22%
Data as of Nov 16, 2018